Page 12 - Indian Pharma Companies

Serum Institute hopes to roll out a Covid-19 vaccine. Is this realistic?

The Pune-based company plans to start trials on people to assess whether the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis can also protect against the Covid-19 virus.

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

Growth prospects, valuations aid Indian pharma firms surpass foreign MNCs

With the pharma sector being rerated, given steady growth prospects and attractive valuations, all the companies, including pharma MNCs, will see greater investor interest

RPG Life Sciences delivers life-saving drugs directly to patients

Despite the pharmaceutical industry having the essential commodities tag, the administration, police and building societies was not allowing movement of people and products

Covid-19 impact: Pharma players join hands to ensure smooth production

Combined capacity utilisation at all-India level is 60-70% - higher than in most other industries

Coronavirus outbreak: Quick USFDA approvals for asthma drug makers

Cipla gets nod for drug from USFDA earlier than expected; Lupin in fray

Coronavirus outbreak: Pharma market grows 9% in March due to panic buying

Cardio-diabetic and respiratory segments clock robust growth

India lifts curbs on exports of 13 active pharmaceutical ingredients

In the first week of March, India restricted the exports of 13 APIs and their formulations to ensure there was no shortage in the domestic market.

Aurobindo Pharma's debt pain recedes after calling off deal with Sandoz

Aurobindo was scheduled to acquire the portfolio with an upfront purchase price of $900 million in cash

The post-COVID-19 world

Policymakers and pharma companies will have to work together to speed up trials of new vaccines and legislate to ensure essential drugs and tests are affordable and available

Lincoln Pharma plans to foray into regulated markets, upgrades facility

The company has upgraded its manufacturing facility at Khatraj near Ahmedabad with Rs 30-crore investment

India scores better than US in regulatory action by USFDA in 2019

From FY15 to FY19, Indian manufacturers received fewer warning letters than Chinese counterparts

Indian drug makers take a hit on quality compliance, R&D investments

The trend is unlikely to reverse in the near term, say experts

Pharma industry considering 'ethics inspectors' to ensure better compliance

Pharma players to meet DoP to discuss suggestions around implementing ethical marketing practices code

Pharma firms plan awareness drive to battle cancer scare in antacid

Indian companies have also been hit in their global business.

Three key reasons why CLSA is bullish on pharma MNCs in India

MNC stocks have outperformed local peers for the first time in over a decade and have also significantly outperformed the Nifty over the last 18 months.

Indian pharmaceutical companies spread business to avoid regulatory ire

Increased USFDA import alerts could be reason for finding alternative sites

FDA observations on Telangana plant a fresh headache for Aurobindo Pharma

The Telangana unit in question is an important one contributing about a fifth to US revenues

USFDA impact: DCGI asks states told to put antacids under scanner

The ranitidine market in India is roughly around Rs 700 crore, with about 180 brands

S&P revises Glenmark outlook to 'negative' on weak operating performance

Glenmark's capex for the first quarter of fiscal 2020 was Rs 190 crore, in line with its guidance